CDKN2A and neoplasm: Inhibition of CDK4/6, or likewise knocking out Cyclin D1 or overexpressing p16INK4A, leads to increased PD-L1 expression in numerous cell lines and preclinical tumor models, including B16 melanoma (109, 110, 112, 113).